$-0.56 EPS Expected for Madrigal Pharmaceuticals, Inc. (MDGL)

July 14, 2018 - By Eula Gilbert

Analysts expect Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) to report $-0.56 EPS on August, 9.They anticipate $0.13 EPS change or 18.84 % from last quarter’s $-0.69 EPS. After having $-0.45 EPS previously, Madrigal Pharmaceuticals, Inc.’s analysts see 24.44 % EPS growth. The stock increased 2.97% or $8.57 during the last trading session, reaching $296.75. About 161,096 shares traded. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has risen 630.32% since July 14, 2017 and is uptrending. It has outperformed by 617.75% the S&P500.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company has market cap of $4.52 billion. The company's lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It currently has negative earnings. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials.

More notable recent Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) news were published by: Streetinsider.com which released: “UPDATE: Evercore ISI Downgrades Madrigal Pharmaceuticals (MDGL) to In Line; See Limited Upside Short of Takeover” on June 19, 2018, also Fool.com with their article: “Cash for NASH: 2 Top Biotech Takeover Targets and 3 Potential Buyers” published on June 15, 2018, Fool.com published: “3 Huge Biotech Winners in 2018 (So Far)” on July 11, 2018. More interesting news about Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) were released by: Seekingalpha.com and their article: “Rounds Report: Potential M&A For Madrigal While The FDA To Incorporate Patient’s Voice In Drug Innovation” published on June 14, 2018 as well as Seekingalpha.com‘s news article titled: “Galmed +20% as Cantor sets Street-high target” with publication date: July 11, 2018.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.